Novocure Announces Addition to Its Board of Directors

Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018.

“We are extremely pleased to welcome Jeri to our board of directors,” said Bill Doyle, Novocure’s Executive Chairman. “Her significant biopharmaceutical and medical device experience as well as her finance, strategy and leadership skills will be invaluable as we grow our glioblastoma (GBM) business and advance our proprietary cancer therapy to commercialize indications beyond GBM.”

Ms. Hilleman is Chief Financial Officer of Intersect ENT (NASDAQ: XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Prior to joining Intersect ENT, she was Chief Financial Officer of Amyris Inc., a multi-national, renewable products company based in California and Brazil, from January 2008 to June 2012. Ms. Hilleman was a member of the board of directors and chair of the audit committee at Xenoport Inc., a commercial biopharmaceutical company, from January 2004 to July 2018. She also served as Chief Financial Officer of Symyx Technologies, a research services, software and instrumentation company, Ocera, a biopharmaceutical company, and Cytel, an immunotherapy company. She is also a director of Minerva Neurosciences (NASDAQ: NERV). Jeri holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2018, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Media and Investor Contact:
Novocure
Ashley Cordova, 212-767-7558
acordova@novocure.com

Source: Novocure

Print Friendly, PDF & Email